Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation

被引:16
|
作者
Salmasian, H. [1 ]
Rohanizadegan, M. [1 ]
Banihosseini, S. [5 ]
Rahimi Darabad, R. [3 ,4 ]
Rabbani-Anari, M. [1 ]
Shakiba, A. [1 ]
Ferrara, J. L. [2 ]
机构
[1] Univ Tehran Med Sci, Students Sci Res Ctr, Tehran 1938833911, Iran
[2] Univ Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI USA
[3] Univ Tehran Med Sci, Fac Pharm, Tehran 1938833911, Iran
[4] Univ Tehran Med Sci, PHarmaceut Sci Res Ctr, Tehran 1938833911, Iran
[5] Univ Tehran Med Sci, Systemat Review Study Grp, Tehran 1938833911, Iran
关键词
BONE-MARROW-TRANSPLANTATION; RANDOMIZED-TRIAL; SHORT-TERM; CYCLOSPORINE; THERAPY; METHYLPREDNISOLONE; PROPHYLAXIS; PREDNISONE; QUALITY; PREVENTION;
D O I
10.1002/14651858.CD005565.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Corticosteroids are commonly used in treatment of acute and chronic graft-versus-host disease (GvHD). Nevertheless, there has been no systematic analysis of effects of their use on the patients' survival and quality of life. Objectives To compare the effect of corticosteroids in treatment of patients with GvHD and to compare the effect of different regimens of corticosteroids. Search strategy We searched MEDLINE (up to July 2008), EMBASE (up to July 2008) and the Cochrane Controlled Trials Register (up to July 2008) to identify relevant studies. All of the references were assessed in order to identify additional trials. Selection criteria Randomized controlled trials of any language were included in the study as long as they met any of the predefined comparisons of interest. The primary outcome in question was the overall survival of the patients. Due to lack of evidence, inclusion criteria was revised during the process of the review to include studies comparing different dosage of corticosteroids. Data collection and analysis All derived citations and abstracts were screened by two independent review authors for relevance. For the potentially relevant trials, the full text was obtained and reviewed by two review authors independently. Two review authors completed data extraction independently. After revising the inclusion criteria, this process was retried to ensure all relevant evidence is included in the review. Main results No studies met the original inclusion criteria but two studies (four articles) met the revised inclusion criteria. As they addressed different clinical questions, meta-analysis was not performed. The outcomes of one study were in favor of efficacy of corticosteroids in inducing an earlier remission of acute GvHD, while the other study reported that early corticosteroid therapy of acute GvHD could not prevent progression of the disease to higher grades, although it was accompanied by a slightly better prognosis in the patients who responded by the fifth day of treatment. Authors' conclusions There is no certain study regarding appropriate use, dose and length of therapy for acute GvHD. Further studies are needed to define the appropriate use of steroids and whether other agents are appropriate as frontline therapy.
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Patients with graft versus host disease after allogenic stem cell transplantation and their quality of life after eight treatment cycles with extracorporeal photopheresis
    Sundholm, M.
    Skovlund, C.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S555 - S555
  • [22] Basiliximab in the treatment of acute graft-versus-host disease after allogeneic stem cell transplantation.
    Ma, X
    Wu, DP
    Sun, AN
    BLOOD, 2005, 106 (11) : 426B - 426B
  • [23] Acute graft-versus-host disease (GVHD) overlapping chronic GVHD after reinduction chemotherapy
    Delgado-Jimenez, Y.
    Goiriz, R.
    Vargas-Diez, E.
    Fraga, J.
    Garcia-Diez, A.
    Fernandez-Herrera, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (02) : 388 - 390
  • [24] Chronic graft-vs-host disease (GVHD) after allogeneic marrow or blood stem cell transplantation
    Anderlini, P
    Przepiorka, D
    Khouri, I
    vanBesien, K
    Mehra, R
    Giralt, S
    Gajewski, J
    Cleary, K
    Champlin, R
    Andersson, B
    Korbling, M
    BLOOD, 1995, 86 (10) : 421 - 421
  • [25] Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): Graft-versus-leukemia (GVL) without acute graft-versus-host-disease (GVHD).
    Khouri, I
    Keating, MJ
    Przepiorka, D
    vanBesien, K
    Gajewski, J
    OBrien, S
    Huh, YO
    Mehra, R
    Giralt, S
    Seong, D
    Korbling, M
    Deisseroth, AB
    Champlin, RE
    BLOOD, 1995, 86 (10) : 1814 - 1814
  • [26] Chronic graft-versus-host disease after allogeneic blood stem cell transplantation
    Przepiorka, D
    Anderlini, P
    Saliba, R
    Cleary, K
    Mehra, R
    Khouri, I
    Huh, YO
    Giralt, S
    Braunschweig, I
    van Besien, K
    Champlin, R
    BLOOD, 2001, 98 (06) : 1695 - 1700
  • [27] Prevalence of oral chronic graft versus host disease after allogeneic stem cell transplantation
    Yamada, Ayaka
    Torihata, Sayaka
    Shimoide, Takeshi
    Lee, Atsushi-Doksa
    Kinoshita, Yuko
    Kawaguchi, Miku
    Ashida, Takashi
    Matsumura, Itaru
    Enomoto, Akifumi
    ORAL SCIENCE INTERNATIONAL, 2024, 21 (02) : 249 - 254
  • [28] Predicting Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation
    Ebeling, Peter R.
    TRANSPLANTATION, 2014, 98 (04) : 380 - 381
  • [29] Cardiac Effects of Chronic Graft-versus-Host Disease after Stem Cell Transplantation
    Dogan, Ali
    Dogdu, Orhan
    Ozdogru, Ibrahim
    Yarlioglues, Mikail
    Kalay, Nihat
    Inanc, Mehmet Tugrul
    Ardic, Idris
    Celik, Ahmet
    Kaynar, Leylagul
    Kurnaz, Fatih
    Eryol, Namik Kemal
    Kaya, Mehmet Gungor
    TEXAS HEART INSTITUTE JOURNAL, 2013, 40 (04) : 428 - 434
  • [30] Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease
    S Kulkarni
    R Powles
    B Sirohi
    J Treleaven
    R Saso
    C Horton
    A Atra
    M Ortin
    C Rudin
    S Goyal
    S Sankpal
    S Meller
    C R Pinkerton
    J Mehta
    S Singhal
    Bone Marrow Transplantation, 2003, 32 : 165 - 170